Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
linear decrease » linear increase (Expand Search)
year increase » linear increase (Expand Search), may increase (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
linear decrease » linear increase (Expand Search)
year increase » linear increase (Expand Search), may increase (Expand Search)
-
481
-
482
-
483
-
484
Trends of HIV related services in Addis Ababa Ethiopia from July 2019 to October 2020.
Published 2024Subjects: -
485
-
486
Trends of maternal health service utilization in Addis Ababa Ethiopia; July 2019 to October 2020.
Published 2024Subjects: -
487
Trends in outpatient services utilizations in Addis Ababa Ethiopia from July 2019 to October 2020.
Published 2024Subjects: -
488
-
489
Trends of diabetes mellitus and hypertension; July 2019 to October 2020 in Addis Ababa Ethiopia.
Published 2024Subjects: -
490
-
491
-
492
Trends of expanded immunization program in Addis Ababa Ethiopia from July 2019 to October 2020.
Published 2024Subjects: -
493
-
494
Effect of ex vivo treatment with rhTGFβ1 or a TGFβ1 inhibitor on monocyte responses to rgE stimulation. Monocytes and NK cells purified from PBMC collected from 10 RZV recipients (demographics in S4 Table) before vaccination (D0) and 90 days post-vaccination (D90) were combined ex vivo and stimulated with VZV-rgE. A subset of D0 monocyte & NK cocultures was also treated with the TGFβ1 inhibitor LY (D0 LY), and a subset of D90 cocultures were supplemented with rhTGFβ1. The graph shows individual data points, means and p values calculated by Friedman test for repeated measures with FDR correction. LY treatment of cells collected on D0 significantly increased their activation to levels similar to D90. Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0.
Published 2025“…Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0.…”
-
495
-
496
Evolution of health burden and life expectancy under different expenditure scenarios.
Published 2025Subjects: -
497
-
498
-
499
Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations.
Published 2025“…<b>(D)</b> Similarly, U251MG cells showed significantly decreased clonogenic potential upon 100ΜM SHG-44 treatment when compared to 100ΜM cis-platin and the untreated control. …”
-
500